August 4th, 2021 by WCBC Radio
Biotechnology company Novavax, based in Gaithersburg, announced Wednesday it has finalized an advanced purchase agreement with the European Commission for up to 200 million doses of its COVID-19 vaccine.
The agreement covers the purchase of up to 100 million doses of the vaccine with the option of another 100 million doses through 2023, the company said. Novavax did not disclose the sum of the purchase.
Novavax reported 90.4% overall efficacy in its Phase 3 clinical trial in the United States and Mexico. In its Phase 3 trials in the United Kingdom, the company reported 89.7% efficacy with 96% efficacy against the original COVID-19 strain.
